A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin

Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters....

Full description

Saved in:
Bibliographic Details
Published inHematology (Luxembourg) Vol. 27; no. 1; pp. 337 - 342
Main Authors Cheong, May Anne, Tan, Chuen Wen, Wong, Wan Hui, Kong, Ming Chai, See, Edmund, Yeang, Shu Hui, Koh, Sei Keng, Shim, Yuan Tying, Lee, Lai Heng, Ng, Heng Joo
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 31.12.2022
Taylor & Francis Group
Subjects
Online AccessGet full text
ISSN1607-8454
1607-8454
DOI10.1080/16078454.2022.2043573

Cover

Loading…
Abstract Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients. A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects. 54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001). We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.
AbstractList Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients. A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects. 54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001). We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.
Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients. A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects. 54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, <0.001; min2: r = 0.485, <0.001; max2: r = 0.578, <0.001; adjusted min1: r = 0.734, <0.001, adjusted min2: r = 0.693, <0.001; adjusted max2: r = 0.751, <0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, = 0.087; min2: r = 0.326, = 0.016; max2: r = 0.437, <0.001; adjusted min1: r = 0.610, <0.001, adjusted min2: r = 0.563, <0.001; adjusted max2: r = 0.642, <0.001). We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.
Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.OBJECTIVESThrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.PATIENTS/METHODSA prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).RESULTS54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.CONCLUSIONWe demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.
Objectives Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.Patients/Methods A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.Results 54 samples were included covering an INR range from 1.33–6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).Conclusion We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it’s role in the evaluation of global haemostatic function.
Author Cheong, May Anne
Wong, Wan Hui
Shim, Yuan Tying
Tan, Chuen Wen
Ng, Heng Joo
See, Edmund
Yeang, Shu Hui
Lee, Lai Heng
Kong, Ming Chai
Koh, Sei Keng
Author_xml – sequence: 1
  givenname: May Anne
  orcidid: 0000-0002-1333-6596
  surname: Cheong
  fullname: Cheong, May Anne
  email: cheong.may.anne@singhealth.com.sg
  organization: Singapore General Hospital
– sequence: 2
  givenname: Chuen Wen
  surname: Tan
  fullname: Tan, Chuen Wen
  organization: Singapore General Hospital
– sequence: 3
  givenname: Wan Hui
  surname: Wong
  fullname: Wong, Wan Hui
  organization: Singapore General Hospital
– sequence: 4
  givenname: Ming Chai
  surname: Kong
  fullname: Kong, Ming Chai
  organization: Singapore General Hospital
– sequence: 5
  givenname: Edmund
  surname: See
  fullname: See, Edmund
  organization: Singapore General Hospital
– sequence: 6
  givenname: Shu Hui
  surname: Yeang
  fullname: Yeang, Shu Hui
  organization: Singapore General Hospital
– sequence: 7
  givenname: Sei Keng
  surname: Koh
  fullname: Koh, Sei Keng
  organization: Singapore General Hospital
– sequence: 8
  givenname: Yuan Tying
  surname: Shim
  fullname: Shim, Yuan Tying
  organization: Singapore General Hospital
– sequence: 9
  givenname: Lai Heng
  surname: Lee
  fullname: Lee, Lai Heng
  organization: Singapore General Hospital
– sequence: 10
  givenname: Heng Joo
  surname: Ng
  fullname: Ng, Heng Joo
  organization: Singapore General Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35255239$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtvFDEQhEcoiDzgJ4DmyGWDn_MQF6IIkkiRuMARWW1POzjy2ovtZbX_Hk9mFyEOcLGt8lfVUtd5cxJiwKZ5TcklJQN5RzvSD0KKS0YYq4fgsufPmrNZX80fJ3-8T5vznB9JJUlPXjSnXDIpGR_Pmm9XrYkpoYfiYmijbcv3FNfahfYBA6ZFhpxh30KYWuNjaXfwE21M66qA32eX24pvKoqh5LbyO0gWkgsvm-cWfMZXh_ui-frp45fr29X955u766v7lZFCltUw2A6lpYgj74UlugM7MjRAB9aBHiiBjlEcjNGyswQGMU6aGkmgF0Rzxi-auyV3ivCoNsmtIe1VBKeehJgeFKTijEfF9GiBU6CoqegNG1FrrNMHLXoqkNast0vWJsUfW8xFrV026D0EjNusWMd7XvctSEXfHNCtXuP0e_BxvRV4vwAmxZwTWmVceVppSeC8okTNZapjmWouUx3KrG75l_s44H--D4vPhbkl2MXkJ1Vg72OyCYJxWfF_R_wCNHu1zQ
CitedBy_id crossref_primary_10_33160_yam_2022_08_013
crossref_primary_10_1016_j_thromres_2025_109268
crossref_primary_10_33160_yam_2022_08_008
crossref_primary_10_1038_s41598_024_60098_3
crossref_primary_10_33086_ijmlst_v5i1_3064
Cites_doi 10.1016/j.thromres.2019.03.022
10.1111/j.1538-7836.2006.01730.x
10.1186/1477-9560-1-7
10.1111/jth.14022
10.1186/1477-9560-13-1
10.1160/TH09-03-0180
10.1111/j.1538-7836.2005.01513.x
10.1002/rth2.12048
10.1111/j.1365-2141.2008.07279.x
10.1159/000073575
10.5482/HAMO-14-02-0016
10.1046/j.1365-2257.2002.00457.x
10.1055/s-0038-1657690
10.1111/j.1538-7836.2006.01848.x
10.1111/jth.12287
ContentType Journal Article
Copyright 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022
Copyright_xml – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.1080/16078454.2022.2043573
DatabaseName Taylor & Francis Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1607-8454
EndPage 342
ExternalDocumentID oai_doaj_org_article_2b9fa31a1eb147c29ebbe6e58b4714e1
35255239
10_1080_16078454_2022_2043573
2043573
Genre Research Article
Journal Article
GroupedDBID ---
002
0YH
1~B
29I
36B
4.4
53G
AALUX
ABDBF
ACGEJ
ACUHS
ADCVX
ADXPE
AENEX
AIJEM
AJWEG
ALMA_UNASSIGNED_HOLDINGS
ARJSQ
BLEHA
BOHLJ
CCCUG
CS3
DU5
E01
EAP
EBC
EBD
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
H13
HCLVR
HZ~
KTTOD
M4Z
MV1
OK1
P76
P7A
P7B
QZIEQ
SV3
TDBHL
TFL
TFW
TUS
~XQ
AAFWJ
AAYXX
AFPKN
CITATION
5VS
ABUPF
AGYJP
AWYRJ
CAG
CGR
COF
CUY
CVF
CZDIS
DRXRE
ECM
EIF
EJD
M46
NPM
7X8
ID FETCH-LOGICAL-c545t-88f6e5f1ee9374f0b6af92eca1826ab810a621e8ccb56f0a849db1c50a740b323
IEDL.DBID 0YH
ISSN 1607-8454
IngestDate Wed Aug 27 01:32:23 EDT 2025
Fri Jul 11 01:22:05 EDT 2025
Wed Feb 19 02:26:13 EST 2025
Thu Apr 24 22:59:22 EDT 2025
Tue Jul 01 02:28:02 EDT 2025
Wed Dec 25 09:05:03 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Anticoagulants
partial thromboplastin time
thrombin
blood coagulation tests
warfarin
Language English
License open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c545t-88f6e5f1ee9374f0b6af92eca1826ab810a621e8ccb56f0a849db1c50a740b323
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-1333-6596
OpenAccessLink https://www.tandfonline.com/doi/abs/10.1080/16078454.2022.2043573
PMID 35255239
PQID 2637320440
PQPubID 23479
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_2b9fa31a1eb147c29ebbe6e58b4714e1
crossref_citationtrail_10_1080_16078454_2022_2043573
informaworld_taylorfrancis_310_1080_16078454_2022_2043573
pubmed_primary_35255239
proquest_miscellaneous_2637320440
crossref_primary_10_1080_16078454_2022_2043573
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-12-31
PublicationDateYYYYMMDD 2022-12-31
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-31
  day: 31
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Hematology (Luxembourg)
PublicationTitleAlternate Hematology
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References CIT0010
CIT0001
CIT0012
CIT0011
CIT0003
CIT0014
CIT0002
CIT0013
CIT0005
CIT0004
CIT0015
CIT0007
CIT0006
CIT0009
CIT0008
References_xml – ident: CIT0006
  doi: 10.1016/j.thromres.2019.03.022
– ident: CIT0010
  doi: 10.1111/j.1538-7836.2006.01730.x
– ident: CIT0015
  doi: 10.1186/1477-9560-1-7
– ident: CIT0008
  doi: 10.1111/jth.14022
– ident: CIT0001
  doi: 10.1186/1477-9560-13-1
– ident: CIT0014
  doi: 10.1160/TH09-03-0180
– ident: CIT0005
  doi: 10.1111/j.1538-7836.2005.01513.x
– ident: CIT0012
  doi: 10.1002/rth2.12048
– ident: CIT0009
  doi: 10.1111/j.1365-2141.2008.07279.x
– ident: CIT0007
  doi: 10.1159/000073575
– ident: CIT0003
  doi: 10.5482/HAMO-14-02-0016
– ident: CIT0004
  doi: 10.1046/j.1365-2257.2002.00457.x
– ident: CIT0013
  doi: 10.1055/s-0038-1657690
– ident: CIT0011
  doi: 10.1111/j.1538-7836.2006.01848.x
– ident: CIT0002
  doi: 10.1111/jth.12287
SSID ssj0022070
Score 2.3182316
Snippet Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays....
Objectives Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global...
SourceID doaj
proquest
pubmed
crossref
informaworld
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 337
SubjectTerms Anticoagulants
Blood Coagulation - drug effects
blood coagulation tests
Blood Coagulation Tests - methods
Humans
Middle Aged
partial thromboplastin time
Prospective Studies
thrombin
Thrombin - drug effects
warfarin
Warfarin - pharmacology
Warfarin - therapeutic use
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PSx0xEA7Fg_RStK36qi0Rel3dJLPZ7FFFkYKeKngpIckmXnSf-Fal_72TH_vQgrxLb0tIYJjMZr4vP74h5CdGUd-DElVTC15Bi1-2aSNLwWwifGtZ2tO9uJTnV_Drurl-Veor3gnL8sDZcYfcdsEIZhguKtA63nlrvfSNsrisgk_EB3PeRKYK1eJow_ReR9WHUUVNQdpD4fH1FWKEVrzJREmw_x-50vdBZ0o-ZxvkU0GN9Chbu0k--OEzWb8o5-JfyJ8j6mKZjXyxjc4DjeUP7pD10pukK52aESebv9QMPXW385E-mycfzcCWLExCsXvRWV1Q7P9sHgJS6eEruTo7_X1yXpXCCZVDQDRWSgX0UGDeI_iAUFtpQse9M5FMGKtYbSRnXjlnGxlqo6DrLXNNbVqoreBii6wN88HvENqCM46DYR0AeLAGEaMUIFXnueytnRGYnKhdURWPxS1uNSvio5PvdfS9Lr6fkYPlsPssq7FqwHGcoWXnqIqdGjBWdIkVvSpWZqR7Pb96TJsiIVcw0WKFAftTMGj8A-Oxihn8_HGhuRSt4LF094xs5yhZmhnFZpHqd9_-h_m75GO0KMtM7pG18eHRf0dINNofKfpfAJvbAr8
  priority: 102
  providerName: Directory of Open Access Journals
Title A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin
URI https://www.tandfonline.com/doi/abs/10.1080/16078454.2022.2043573
https://www.ncbi.nlm.nih.gov/pubmed/35255239
https://www.proquest.com/docview/2637320440
https://doaj.org/article/2b9fa31a1eb147c29ebbe6e58b4714e1
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSIgLAspjeVRG6jUQ2xPHORbUalWpPVGJHirL9tq9lATtplT8e2YcZwVIVQ-9JZatjMfjzMPjbxjbRylarcCoqqmVrKDFJ9-05KWgNlGx9SLHdE9O9fIMjr83czbhpqRVkg-dJqCI_K-mze38Zs6I-0yYaAZyRETSXSrU-K16yB5Jwl5Hka7Pl1ufSyIx88Wd24b-o5Iycv9_uKW3W59ZCx09Y0-L-cgPpvV-zh7E_gV7fFIOyHfZxQEPVG9jynDjQ-JUB-EHur_8MgNM52Y0mN1vjvPn4WoY-Y37FYkMbJkQSjh2L4CrG479b9w6oU_dv2RnR4ffvi6rUkGhCmgZjZUxSccmiRjRCoFUe-1SJ2Nw5FU4b0TttBTRhOAbnWpnoFt5EZratVB7JdUrttMPfXzDeAvBBQlOdAAQwTs0HbUCbboo9cr7BYOZiTYUeHGqcnFlRUEhnXlvife28H7BPm2H_ZzwNe4a8IVWaNuZ4LFzw7C-tGW3Wem75JRwAjURtEF20fuInDAedTFEsWDd3-trxxwdSVMpE6vuIODjLAwWtyKdr7g-DtcbK7VqlaQa3gv2epKSLZmEOos-f_f2Hl9-x57Q6wQz-Z7tjOvr-AFNotHvZaHfywGFPzcU_6o
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSNALKs8utGAkroHYnjjOsSCqLXR7aqVyQJbttXtpE7RNqfj3zDjJqiBVPXCLnLEyGs9kHra_Yew9atFyCUYVValkATU--aqmLAW9iYq1F7mmuzjS8xP4elqd3rgLQ8cqKYdOA1BE_leTcVMxejoS95FA0Qzkkoiky1To8mt1nz2oDDp71Ony-3yddEnkZrq5c9vUv3xShu7_B7j09vAzu6H9LfZ4jB_53rDgT9i92D5lDxfjDvkz9mOPB2q4MRxx413i1AjhAvNffpYRpvMwRszuN0cB8HDe9fza_YrEBo4MECUcyUfE1UuO9NdulTCpbp-zk_0vx5_nxdhCoQgYGvWFMUnHKokYMQyBVHrtUiNjcJRWOG9E6bQU0YTgK51KZ6BZehGq0tVQeiXVC7bRdm3cZryG4IIEJxoAiOAdxo5agTZNlHrp_YzBJEQbRnxxanNxbsUIQzrJ3pLs7Sj7GfuwnvZzANi4a8InWqE1MeFj54FudWZHc7PSN8kp4QS6IqiDbKL3ESVhPDpjiGLGmpvra_tcHklDLxOr7mDg3aQMFm2RNlhcG7urSyu1qpWkJt4z9nLQkjWbBDuLSX_z6j--_JY9mh8vDu3hwdG312yTXg2Ykztso19dxV2Mj3r_JhvAHzgiAkE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSBUXxJvlaSSugfgRxz6Wx2p5tOJAJTggy3bsXkpS7aat-u-ZcZwVIFU9cIscW5mMx5n57Mk3hLwCK-o6qUXV1IJXsoUr37SIUsCbiNh6lvd09w_U6lB--t7M2YSbklaJGDpNRBH5W42L-6RLc0bcG-RE0zLviHD8lwo8fiuukxuNNhyzuuofqy3m4iDM_OPOZUP_ckmZuf8f3tLLo8_shZa3ya0SPtK9ab7vkGuxv0t298sB-T3yc48GrLcxZbjRIVGsg_AL4C89ygTTuRkCZndB4f1pOB5Geu7OIooBLRNDCYXuhXB1Q6H_uVsnwNT9fXK4_PDt3aoqFRSqAJHRWGmdVGwSixGiEJlqr1wyPAaHqMJ5zWqnOIs6BN-oVDstTedZaGrXytoLLh6QnX7o4yNCWxlc4NIxI6WM0jsIHZWQSpvIVef9gshZiTYUenGscnFsWWEhnXVvUfe26H5BXm-HnUz8GlcNeIsztO2M9Ni5YVgf2bLaLPcmOcEcA08k28BN9D6CJrQHXywjWxDz5_zaMe-OpKmUiRVXCPByNgYLSxHPV1wfh9ON5Uq0gmMN7wV5OFnJVkxknQXMbx7_x5NfkN2v75f2y8eDz0_ITbwzMU4-JTvj-jQ-g-ho9M-z_f8GkQEBag
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+correlation+of+thrombin+generation+assay+and+clot+waveform+analysis+in+patients+on+warfarin&rft.jtitle=Hematology+%28Luxembourg%29&rft.au=Cheong%2C+May+Anne&rft.au=Tan%2C+Chuen+Wen&rft.au=Wong%2C+Wan+Hui&rft.au=Kong%2C+Ming+Chai&rft.date=2022-12-31&rft.pub=Taylor+%26+Francis&rft.eissn=1607-8454&rft.volume=27&rft.issue=1&rft.spage=337&rft.epage=342&rft_id=info:doi/10.1080%2F16078454.2022.2043573&rft.externalDBID=0YH&rft.externalDocID=2043573
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1607-8454&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1607-8454&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1607-8454&client=summon